Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Study Overview
=================
Brief Summary
-----------------
The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment.

Detailed Description
-----------------
Primary objective The Objective of this study is to compare 2-year retention rate of topiramate, levetiracetam and oxcarbazepine in a long term epilepsy treatment. Secondary objective The main secondary objective of this study is to evaluate confounding factors associated with retention rate of topiramate compared with other anticonvulsants. Baseline characteristics Seizure Type Gender Age of onset Treatment regimen Number of concomitant medication Type of drug combination Final target dose Titration speed Other secondary objectives The other secondary objectives of this study are to compare followings by each medication: Rate of seizure reduction (≥75%, ≥50%) Rate of seizure freedom

Official Title
-----------------
A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment

Conditions
-----------------
Epilepsy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects who began their treatment with topiramate, levetiracetam or oxcarbazepine as mono or add-on therapy with conventional drugs. Subjects who are with partial or generalized epilepsy Exclusion Criteria: Subjects who administered combination therapy in topiramate, levetiracetam or oxcarbazepine Subjects who have past experience of surgery for epilepsy treatment Subjects who were not followed up for at least 1 year

Ages Eligible for Study
-----------------
Minimum Age: 15 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Topiramate<br>Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with topiramate as mono or add-on therapy with conventional drugs. | |
| Levetiracetam<br>Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with levetiracetam as mono or add-on therapy with conventional drugs. | |
| Oxcarbazepine<br>Subjects who newly visited to the investigator institution during January 1st 2006 to December 31st of 2010 and began their treatment with oxcarbazepine as mono or add-on therapy with conventional drugs. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Retention rate of topiramate, levetiracetam and oxcarbazepine during 24 months of treatment | Overall retention rates of three treatment groups at two years will be presented in patient number (% of continuation or discontinuation). | 24months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the confounding factors affecting the retention rate | -Confounding factors associated with retention rate : Seizure Type, gender, age, treatment regimen, number of concomitant medication, type of drug combination, final target dose, titration speed | 24 months | 
| Evaluate the response rate through seizure reduction (≥75%, ≥50%) in 2-year treatment with each antiepileptic drugs (topiramate, levetiracetam, oxcarbazepine) |  | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
topiramate, oxcarbazepine, levetiracetam, retention rate